certolizumab pegolJoe Segen2016-12-25T03:04:02+00:00
Other names Cimzia, CPD870
A humanised monoclonal antibody that inhibits tumour-necrosis factor-alpha–TNF-alpha, which is FDA-approved for managing Crohn’s disease* and rheumatoid arthritis†.
*Per PRECISE-1 and PRECISE-2 trials †Per RAPID-1 and RAPID-2 trials
Adverse effects Heart failure, dizziness, paraesthesias of extremities, allergic reactions, immune suppression, lupus-like symptoms, increased risk of infections and lymphomas
Product literature, UCB, Inc.